Stiefel - About the company
Stiefel is an acquired company based in Durham (United States), founded in 1847. It operates as a Global biopharma uniting science, technology, and talent to get ahead of disease. The company has 167 active competitors, including 41 funded and 59 that have exited. Its top competitors include companies like Revance Therapeutics, Evolus and Dermavant.
Company Details
Global biopharma uniting science, technology, and talent to get ahead of disease. Focused on innovative research and development across respiratory, immunology, inflammation, oncology, HIV, and infectious diseases. Committed to positively impacting global health through access programs, strategic partnerships, and responsible pricing. Dedicated to environmental sustainability, ethical standards, and inclusion. Offers pharmaceutical products, vaccines, and healthcare solutions. Engages with healthcare professionals, patients, and investors. Operates globally with a focus on scientific publications, clinical trials, and data transparency. Strives to improve access to healthcare and address unmet medical needs.
- Website
- stiefel.com
- Social
- Registered Address
- Philadelphia, Pennsylvania
Key Metrics
Founded Year
1847
Location
Durham, United States
Stage
Acquired
Ranked
146th among 167 active competitors
Employee Count
229 as on Apr 30, 2026
Investment & Acquisitions
Similar Companies
Exit Details
Acquired by GSK (Apr 19, 2009)
Legal entities associated with Stiefel
Stiefel is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
STIEFEL LABORATORIES, INC. CIN: 141255448 , United States, Active | Dec 26, 999 | - | 133 (As on Dec 31, 2017) | - |
GSK PHARMA INDIA PRIVATE LIMITED CIN: U24239MH2000PTC126937 , India, Active | Jun 02, 2000 | $3.77M (As on Mar 31, 2025) | - |
Stiefel's acquisition details
Click here to take a look at Stiefel's acquisition in detail
Sign up to download Stiefel's company profile
Stiefel's funding and investors
Stiefel is a funded company.
Stiefel's founders and board of directors
Founder? Claim ProfileStiefel's employee count trend
Stiefel has 229 employees as of Apr 26. Here is Stiefel's employee count trend over the years:
Uncover Stiefel's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Stiefel's Competitors and alternates
Top competitors of Stiefel include Revance Therapeutics, Evolus and Dermavant. Here is the list of Top 10 competitors of Stiefel, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Revance Therapeutics 2002, Newark (United States), Acquired | Developer of neurotoxin aesthetic and therapeutic products for skin treatments | $155M | 72/100 | |
2nd | Evolus 2012, Irvine (United States), Public | Developer of aesthetic treatments and procedures | $500K | 67/100 | |
3rd | Dermavant 2016, Phoenix (United States), Acquired | Developer of small molecule based therapeutics for the treatment of inflammatory skin diseases | $160M | 61/100 | |
4th | Biopharma company focused on developing drugs for skin disorders | $51M | - | 61/100 | |
5th | Sol-Gel Technologies 1998, United States, Public | Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis. | $26M | 59/100 | |
6th | Developer of recombinant human collagen for regenerative medicine and aesthetics | $16.3M | 59/100 | ||
7th |  Lineage Cell Therapeutics 1990, Carlsbad (United States), Public | Developer of cell based therapies for the treatment of cancer, eye disease and spinal disorders | $45.8M | 59/100 | |
8th | Biofrontera 1997, Leverkusen (Germany), Public | Developer of therapies for actinic keratosis using photodynamic therapy | - | 56/100 | |
9th |  Medytox 2000, Seoul (South Korea), Public | Developing botulinum toxins, synthetic drugs, supplements & medical devices | - | 55/100 | |
10th | Clock.bio 2020, Cambridge (United Kingdom), Seed | Developer of treatments for age-related diseases using human pluripotent stem cells | $9.93M | 55/100 | |
146th | Stiefel 1847, Durham (United States), Acquired | Global biopharma uniting science, technology, and talent to get ahead of disease | - | - | 28/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Stiefel's competitors? Click here to see the top ones
Stiefel's Investments and acquisitions
Stiefel has acquired 2 companies including Barrier Therapeutics and Connetics Corporation. Stiefel has not made any investments as of now.Reports related to Stiefel
Here is the latest report on Stiefel's sector:
News related to Stiefel
•
Agrofresh builds upon senior leadership through executive appointmentsAgroPages•Apr 06, 2023•AgroFresh, Pfizer, Noven, Stiefel and 2 others
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Stiefel
Explore our recently published companies
- Channel Performance - 2001 founded, Unfunded company
- Worm - 2024 founded, Seed company
- Pharmaron - Srinagar based, 2025 founded, Unfunded company
- Primecontrol - India based, Unfunded company
- Asia Industries Material Handling Equipment - Pasay based, 1992 founded, Unfunded company
- 2500 UNION HILLS - 2015 founded, Unfunded company
